Cargando…
Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial
Background: Docetaxel is an important chemotherapy-agent for breast cancer treatment. One of its side-effects is weight gain, which increases the all-cause mortality rate. Considering gut microbiota is one important factor for weight regulation, we hypothesized that probiotics could be potentially u...
Autores principales: | Juan, Zhang, Qing, Zhang, Yongping, Liang, Qian, Liyuan, Wu, Wei, Wen, Yanguang, Tong, Jianbin, Ding, Boni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675585/ https://www.ncbi.nlm.nih.gov/pubmed/34926547 http://dx.doi.org/10.3389/fnut.2021.762929 |
Ejemplares similares
-
Corrigendum: Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients—A single-center, randomized, double-blind, and placebo-controlled trial
por: Juan, Zhang, et al.
Publicado: (2023) -
Efficacy of Probiotics in Children and Adolescents With Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
por: de Andrade, Paula Danielle Santa Maria Albuquerque, et al.
Publicado: (2022) -
Effects of a Probiotic Formulation on Seasonal Allergic Rhinitis in Adults—A Randomized Double-Blind Placebo-Controlled Trial: The Probiotics for Hay Fever Trial
por: Ried, Karin, et al.
Publicado: (2022) -
The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial
por: Kong, Xue-Jun, et al.
Publicado: (2021) -
Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study
por: Peng, Li Vern, et al.
Publicado: (2022)